Cargando…

Outcomes following I-131 treatment with cumulative dose exceeding or equal to 600 mCi in differentiated thyroid carcinoma patients

To evaluate treatment outcomes following radioactive iodine (RAI) treatment with a cumulative dose of ≥≥600 mCi in differentiated thyroid carcinoma (DTC) patients, a retrospective review of medical records was done in 176 DTC patients with a cumulative dose of ≥600 mCi from January 1993 to December...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaewput, Chalermrat, Pusuwan, Pawana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034781/ https://www.ncbi.nlm.nih.gov/pubmed/33850490 http://dx.doi.org/10.4103/wjnm.WJNM_49_20

Ejemplares similares

Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in Graves’ disease
por: Zaman, Maseeh uz, et al.
Publicado: (2015)

30 mCi exploratory scan for two-step dosimetric (131)I therapy in differentiated thyroid cancer patients: A novel approach and case report
por: Wu, Di, et al.
Publicado: (2020)

Fixed 30 mCi (1110 MBq) (131)I-iodine therapy in autonomously functioning nodules: Single toxic nodule as a predictive factor of success
por: Pereira, Lívia Stela Bueno, et al.
Publicado: (2021)

Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation
por: Jeon, Eon Ju, et al.
Publicado: (2014)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy
por: Súss, Shirlei Kugler Aiçar, et al.
Publicado: (2018)

Unfavorable efficacy to (131)I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb
por: Zhang, Na, et al.
Publicado: (2017)

Role of Combined (68)Ga DOTA-Peptides and (18)F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
por: Kaewput, Chalermrat, et al.
Publicado: (2022)

Thyroid dose assessments due to inhalation of (131)I for nuclear medicine workers
por: Liu, Gang, et al.
Publicado: (2022)

Thyroid Remnant Estimation by Diagnostic Dose (131) I Scintigraphy or (99m) T c O (4) (−) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131) I Imaging
por: Liu, Guanghui, et al.
Publicado: (2016)

Automated segmentation of lung, liver, and liver tumors from Tc‐99m MAA SPECT/CT images for Y‐90 radioembolization using convolutional neural networks
por: Chaichana, Anucha, et al.
Publicado: (2021)

I-131 Dose Response for Incident Thyroid Cancers in Ukraine Related to the Chornobyl Accident
por: Brenner, Alina V., et al.
Publicado: (2011)

MON-559 Inappropriate Dosing of I-131 in Non-Metastatic Differentiated Thyroid Cancer
por: Alzenaidi, Ahlam, et al.
Publicado: (2019)

Correlation between Standardized Uptake Value of (68)Ga-DOTA-NOC Positron Emission Tomography/Computed Tomography and Pathological Classification of Neuroendocrine Tumors
por: Kaewput, Chalermrat, et al.
Publicado: (2018)

Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?
por: Shinto, Ajit S., et al.
Publicado: (2013)

Induction of Leukaemia by (131)I Treatment of Thyroid Carcinoma
por: Brincker, H., et al.
Publicado: (1973)

Feasibility and long-term results of focused radioguided parathyroidectomy using a "low" 37 MBq (1 mCi) (99m)Tc-sestamibi protocol
por: Rubello, Domenico, et al.
Publicado: (2006)

The influence of thionamides on intra-thyroidal uptake of (131)I during radioiodine-131 treatment of Graves’ disease
por: Happel, Christian, et al.
Publicado: (2023)

The Molecular Effect of Diagnostic Absorbed Doses from (131)I on Papillary Thyroid Cancer Cells In Vitro
por: Stasiołek, Mariusz, et al.
Publicado: (2017)

Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
por: Ezziddin, Samer, et al.
Publicado: (2012)

An indirect high iodine ((131)I) effective dose used for thyroid ablation in patients with thyroid cancer. Is the method of measurement important?
por: Al‐Shakhrah, Issa A.
Publicado: (2020)

Transcriptional response to (131)I exposure of rat thyroid gland
por: Rudqvist, Nils, et al.
Publicado: (2017)

Dosimetric analysis of (123)I, (125)I and (131)I in thyroid follicle models
por: Josefsson, Anders, et al.
Publicado: (2014)

(131)I thyroid activity and committed dose assessment among family members of patients treated with radioactive iodine
por: Brudecki, K., et al.
Publicado: (2020)

Impact of thyroiditis on (131)I uptake during ablative therapy for differentiated thyroid cancer
por: Lim, Eugenie S, et al.
Publicado: (2019)

Iodine-131 and Thyroid Function
por: Sun, Wenjie
Publicado: (2014)

Neuropsychological comparison of incident MCI and prevalent MCI
por: Hansen, Allison, et al.
Publicado: (2018)

Response: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (Endocrinol Metab 2014;29:33-9, Eon Ju Jeon et al.)
por: Jeon, Eon Ju, et al.
Publicado: (2014)

Letter: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (Endocrinol Metab 2014;29:33-9, Eon Ju Jeon et al.)
por: Jung, Chan-Hee
Publicado: (2014)

I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy
por: Probst, Stephan, et al.
Publicado: (2018)

Psychological impact of (131)I radioprotection measures on thyroid cancer patients
por: BARBUS, ELENA, et al.
Publicado: (2018)

I(131) Accumulation in Hydrocele in the Setting of Metastatic Papillary Carcinoma Thyroid
por: Seetharam, SJ, et al.
Publicado: (2022)

Area Dose–Response and Radiation Origin of Childhood Thyroid Cancer in Fukushima Based on Thyroid Dose in UNSCEAR 2020/2021: High (131)I Exposure Comparable to Chernobyl
por: Kato, Toshiko, et al.
Publicado: (2023)

The Study of External Dose Rate and Retained Body Activity of Patients Receiving (131)I Therapy for Differentiated Thyroid Carcinoma
por: Zhang, Haiying, et al.
Publicado: (2014)

A practical method of I-131 thyroid cancer therapy dose optimization using estimated effective renal clearance
por: Howard, Brandon A, et al.
Publicado: (2017)

Manual de electrónica, Diseño con C.I. : realizacion de diseños con C.I. normalizados /
por: Meiksin, Z. H.
Publicado: (1992)

Values of (99m)Tc-methoxyisobutylisonitrile imaging after first-time large-dose (131)I therapy in treating differentiated thyroid cancer
por: Pan, Xiaomei, et al.
Publicado: (2016)

Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study
por: Mester, Alexandru, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_br343och2ngvtntnotdn8sdqr6